Paradigm Biopharmaceuticals Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.


Paradigm Shift


Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.


Understanding complexity

Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.


We develop therapeutics targeting multiple pathways involved in injury

Our focus

Pentosan Polysulphate Sodium (PPS)

We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.



Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.


Recent Highlights

Click here for all ASX announcements.

Paradigm reports successful Ross River Phase 2A Clinical Trial

4th June 2019

Paradigm is pleased to announce that it met its primary end point of safety in its pilot phase 2A randomised, double-blind placebo-controlled, multicentre clinical trial in participants with Ross River virus (RRV) induced arthralgia …


Paradigm successfully completes Institutional Entitlement Offer and Placement

17th April 2019

ASX listed biotechnology company Paradigm Biopharmaceuticals Limited is pleased to announce the successful completion of the fund raising by the receipt of its commitments for its $51.6m placement and the $9.8m institutional component of its fully underwritten 1 for 8 accelerated non-renounceable entitlement offer …


Paradigm corporate update: May 2019

8th May 2019

Paradigm Biopharmaceuticals Ltd is today pleased to provide the following update on its clinical programs and commercial progress..


Inflammation is a complex biological response to injury, infection or allergy

Key Statistics


Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.

*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016

Osteoarthritis (OA)

OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.

*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September

Bone Marrow Edema (BME)

Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.

Bone Marrow Edema (BME)

>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)

Research & Development

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.